Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667377 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 387
- Enrollment target
NCT04667377 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 387 participants.
The verdict
NCT04667377, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 387 participants
- Enrollment target
Study Summary
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine. Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.
Interventions
- DRUG Placebo
- DRUG BI 456906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04667377
The ClinicalTrials.gov registry entry for NCT04667377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04667377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04667377 about?
NCT04667377 is a clinical study titled "A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight". This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Par...
What is the current status of trial NCT04667377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 387 participants. The study started on 2021-03-08. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT04667377?
The interventions under investigation include: Placebo (DRUG), BI 456906 (DRUG).
Who is sponsoring clinical trial NCT04667377?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.